Navigation Links
MD Bioproducts releases HLA-B27 subtype specific antibody.
Date:5/29/2012

ST. PAUL, Minn., May 29, 2012 /PRNewswire-iReach/ -- MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

(Photo:  http://photos.prnewswire.com/prnh/20120529/CG15198)

Ankylosing spondylitis (AS) is a chronc inflammatory arthritis. It is characterized by inflammation of the joints between the spinal bones and the joints between the spine and pelvis. It is a long term conditin where the affected joints may fuse together causing a significant loss of quality of life. The pathogenesis of AS remains highly unresolved. While it is known that HLA-B27 is strongly associated with AS, there is subtype variability with a particularly strong association with HLA-B*2704 and HLA-B*2705, which might be due to differential rates of folding. Human leukocyte antigens (HLA) play a central role in the immune system recognizing self from non-self. It is also known that endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms are associated with AS. ERAP1 is an aminopeptidase resident in the edoplasmic reticulum (ER) functioning in N-terminal peptide trimming for pHLA presentation.

The MARB4-reactive population of HLA-B27 molecules appears to be generated particularly when the activity of the ER aminopeptidase ERAP1 is impaired, either by down-regulation or specific point mutations. Since ERAP1 activity appears to be impaired in patients with ankylosing spondylitis (AS), MARB4 reactivity is likely to increase in these patients. Most interesting is the ability of clone MARB4 to distinguish between AS-associated and non-associated HLA-B27 subtypes. The MARB4 clone may possibly be useful to detect early signs of inflammatory episodes in AS patients and thus the anti-HLA-B*2705 (clone MARB4) can thus be expected to be of diagnostic value.

The HLA-B27 antibody is a nice enhancement to the already robust line of arthritis-related research products, including collagens, antibodies, ELISAs and the ArthritoMab(TM) antibody cocktail for the induction of the rapid Collagen Induced Arthritis (CAIA) Model. The HLA-B*2705 antibody is available for pre-order with shipping availability in mid-June.

About MD Bioproducts

MD Bioproducts, a division of privately-owned preclinical CRO MD Biosciences, offers products for use in inflammations, endocrinology, neurology and metabolics research. To learn more about the extensive research products offered by MD Bioproducts, please visit the website at mdbioproducts.com. For more information on contract services offered through MD Biosciences, please visit mdbiosciences.com.

Media Contact: Amy Clausen, MD Biosciences, 651-641-2881, amy@mdbiosciences.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MD Bioproducts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... a historic vote among its members this weekend, the Shinnecock Indian Nation ... and dispensary on tribal land near Southampton . ... for patients in the state,s Medical Cannabis Program. --> ... in the state,s Medical Cannabis Program. --> Tribal members ... designation from the State of New York as ...
(Date:2/8/2016)... Feb. 8, 2016 http://www.researchandmarkets.com/research/x6mkjm/knee ... "Knee Reconstruction Devices Market by Product Type (Primary ... Geography (U.S., Canada, Eu-5, Japan, Bric, Turkey, Indonesia ... report to their offering. --> ... "Knee Reconstruction Devices Market by Product Type ...
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
Breaking Medicine Technology:
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to ... This event brings together top non-profit leaders, ultimate organizations, and coaches from around the ... Iani, Bay Area Disc Program Director of Youth and Education, describes this year YUCC ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
Breaking Medicine News(10 mins):